Abstract
A group of 43 healthy neonates born from HBsAg-positive mothers were evaluated for the presence of protective HBsAb titre after administration of hepatitis B plasma-derived vaccine and hepatitis B hyperimmune-globulin. At 36 months of life we found that a significant number of children had a low HBsAb serum level. This suggests that a close serologic follow-up is necessary to evaluate the optimal timing for the administration of a booster dose of the vaccine.
| Original language | English |
|---|---|
| Pages (from-to) | 195-198 |
| Number of pages | 4 |
| Journal | Microbiologica |
| Volume | 14 |
| Issue number | 3 |
| Publication status | Published - Jul 1991 |
Fingerprint
ASJC Scopus subject areas
- Applied Microbiology and Biotechnology
Cite this
Duration of immune protection after hepatitis B vaccine in newborns from HBsAg-positive carrier mothers. / Belloni, C.; Orsolini, P.; Soldini, L.; Campisi, D.; Chiesa, A.; Ciceri, R.; Filice, G.
In: Microbiologica, Vol. 14, No. 3, 07.1991, p. 195-198.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Duration of immune protection after hepatitis B vaccine in newborns from HBsAg-positive carrier mothers.
AU - Belloni, C.
AU - Orsolini, P.
AU - Soldini, L.
AU - Campisi, D.
AU - Chiesa, A.
AU - Ciceri, R.
AU - Filice, G.
PY - 1991/7
Y1 - 1991/7
N2 - A group of 43 healthy neonates born from HBsAg-positive mothers were evaluated for the presence of protective HBsAb titre after administration of hepatitis B plasma-derived vaccine and hepatitis B hyperimmune-globulin. At 36 months of life we found that a significant number of children had a low HBsAb serum level. This suggests that a close serologic follow-up is necessary to evaluate the optimal timing for the administration of a booster dose of the vaccine.
AB - A group of 43 healthy neonates born from HBsAg-positive mothers were evaluated for the presence of protective HBsAb titre after administration of hepatitis B plasma-derived vaccine and hepatitis B hyperimmune-globulin. At 36 months of life we found that a significant number of children had a low HBsAb serum level. This suggests that a close serologic follow-up is necessary to evaluate the optimal timing for the administration of a booster dose of the vaccine.
UR - http://www.scopus.com/inward/record.url?scp=0026197120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026197120&partnerID=8YFLogxK
M3 - Article
C2 - 1833611
AN - SCOPUS:0026197120
VL - 14
SP - 195
EP - 198
JO - Microbiologica
JF - Microbiologica
SN - 0391-5352
IS - 3
ER -